These reports, in combination with our data, suggest that aberrant modulation of apoC-I in the diseased brain may provide a novel therapeutic target not only for AD but also for other neurodegenerative diseases in which the innate immune response contributes to neuronal stress and degeneration. The gene discussed is APOC1; the disease is neurodegenerative disease.